MX2022006146A - Metodos y composiciones para la neuroproteccion. - Google Patents
Metodos y composiciones para la neuroproteccion.Info
- Publication number
- MX2022006146A MX2022006146A MX2022006146A MX2022006146A MX2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- neuroprotection
- diseases associated
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
- C12Y302/02006—NAD(P)+ nucleosidase (3.2.2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940437P | 2019-11-26 | 2019-11-26 | |
| PCT/US2020/062289 WO2021108602A1 (en) | 2019-11-26 | 2020-11-25 | Methods and compositions for neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006146A true MX2022006146A (es) | 2022-10-18 |
Family
ID=74046136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006146A MX2022006146A (es) | 2019-11-26 | 2020-11-25 | Metodos y composiciones para la neuroproteccion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12595481B2 (https=) |
| EP (1) | EP4065714A1 (https=) |
| JP (2) | JP7528212B2 (https=) |
| KR (1) | KR20220119366A (https=) |
| CN (1) | CN115176002A (https=) |
| AU (1) | AU2020391206A1 (https=) |
| BR (1) | BR112022009772A2 (https=) |
| IL (1) | IL293123A (https=) |
| MX (1) | MX2022006146A (https=) |
| TW (1) | TW202134436A (https=) |
| WO (1) | WO2021108602A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065714A1 (en) * | 2019-11-26 | 2022-10-05 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
| PE20242222A1 (es) * | 2022-03-14 | 2024-11-19 | Lilly Co Eli | Agentes de interferencia de arn de sarm1 |
| CN116059367B (zh) * | 2022-07-15 | 2025-02-18 | 浙江乘时佳生物科技有限公司 | 一种治疗阿尔茨海默症的sarm1抑制剂 |
| JP2025523905A (ja) * | 2022-07-21 | 2025-07-25 | アミリックス ファーマシューティカルズ，インコーポレイティッド | オリゴヌクレオチド組成物及びその方法 |
| TW202547525A (zh) | 2024-02-02 | 2025-12-16 | 美商美國禮來大藥廠 | SARM1 RNAi藥劑 |
| GB202408068D0 (en) | 2024-06-06 | 2024-07-24 | Univ London | Treatment of cancer of the central nervous system |
| WO2025261431A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海拓界生物医药科技有限公司 | 靶向SARM1的RNAi剂及其医药用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040096830A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of protein kinase D2 expression |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| US7901882B2 (en) * | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| JP2013003911A (ja) * | 2011-06-17 | 2013-01-07 | Sony Corp | 電子機器、電子機器の制御方法およびプログラム |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| JP7198489B2 (ja) * | 2016-03-23 | 2023-01-04 | 国立大学法人 岡山大学 | リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用 |
| AU2017292173B2 (en) | 2016-07-06 | 2022-01-13 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| WO2018057989A1 (en) | 2016-09-24 | 2018-03-29 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| EP3585897A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
| US12576130B2 (en) * | 2017-10-18 | 2026-03-17 | Washington University | Dominant negative SARM1 molecules comprising a substitution at position 189, 190, 193, 194, 570 and/or 685 of SARM1 |
| US12448374B2 (en) * | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7481329B2 (ja) | 2018-06-07 | 2024-05-10 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| EP4065714A1 (en) * | 2019-11-26 | 2022-10-05 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
-
2020
- 2020-11-25 EP EP20829411.6A patent/EP4065714A1/en active Pending
- 2020-11-25 BR BR112022009772A patent/BR112022009772A2/pt not_active IP Right Cessation
- 2020-11-25 JP JP2022530807A patent/JP7528212B2/ja active Active
- 2020-11-25 AU AU2020391206A patent/AU2020391206A1/en not_active Abandoned
- 2020-11-25 IL IL293123A patent/IL293123A/en unknown
- 2020-11-25 MX MX2022006146A patent/MX2022006146A/es unknown
- 2020-11-25 CN CN202080082124.2A patent/CN115176002A/zh active Pending
- 2020-11-25 TW TW109141403A patent/TW202134436A/zh unknown
- 2020-11-25 US US17/778,567 patent/US12595481B2/en active Active
- 2020-11-25 WO PCT/US2020/062289 patent/WO2021108602A1/en not_active Ceased
- 2020-11-25 KR KR1020227017020A patent/KR20220119366A/ko not_active Withdrawn
-
2024
- 2024-05-08 JP JP2024075968A patent/JP7796797B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220119366A (ko) | 2022-08-29 |
| JP2024112834A (ja) | 2024-08-21 |
| US20230242909A1 (en) | 2023-08-03 |
| US12595481B2 (en) | 2026-04-07 |
| JP7528212B2 (ja) | 2024-08-05 |
| TW202134436A (zh) | 2021-09-16 |
| JP7796797B2 (ja) | 2026-01-09 |
| JP2023503994A (ja) | 2023-02-01 |
| WO2021108602A1 (en) | 2021-06-03 |
| IL293123A (en) | 2022-07-01 |
| AU2020391206A1 (en) | 2022-05-19 |
| CA3159374A1 (en) | 2021-06-03 |
| CN115176002A (zh) | 2022-10-11 |
| BR112022009772A2 (pt) | 2022-08-16 |
| EP4065714A1 (en) | 2022-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006146A (es) | Metodos y composiciones para la neuroproteccion. | |
| MX2025010269A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| PH12018501065A1 (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| NZ733882A (en) | Compositions for modulating c9orf72 expression | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| EP4025590A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| WO2008092099A3 (en) | Compositions and methods for treating hematopoietic malignancies | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| EP4077690A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| MX359337B (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
| WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
| EP3823593A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM | |
| PH12018501045A1 (en) | Treatment of retinal degeneration using progenitor cells | |
| IL290351A (en) | Compositions and methods for the treatment of neurological diseases | |
| IL285036A (en) | Methods and preparations for the treatment of cancer | |
| HK40082396A (en) | Methods and compositions for treating cancer | |
| HK40079012A (en) | Methods and compositions for treating cancer | |
| HK40072464A (en) | Compositions and methods for treating cancer |